Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Urano

Showing results (151-160 of 345) with videos related to

Pageof 35
Sort By:
International Journal of Oncology|May 17, 2011
Frequent p53 mutations on exons-5 and exon-8 in human primary gastric-cancerS Fushida, T Urano, H Tsuruta, et al.
Thrombosis Research|October 1, 1990
Fluctuation of TPA and PAI-1 antigen levels in plasma: difference of their fluctuation patterns between male and femaleT Urano, K Sumiyoshi, M Nakamura, et al.
Thrombosis Research|October 15, 1990
Fluctuation of tPA and PAI-1 antigen levels in plasma: difference of their fluctuation patterns between male and femaleT Urano, K Sumiyoshi, M Nakamura, et al.
Neuroscience Research|April 22, 1999
Neuronal degeneration and a decrease in laminin-like immunoreactivity is associated with elevated tissue-type plasminogen activator in the rat hippocampus after kainic acid injectionN Nagai, T Urano, A Endo, et al.
American Heart Journal|May 29, 1999
Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertensionK Sakata, M Shirotani, H Yoshida, et al.
International Journal of Cancer|August 19, 1993
Reduced expression of nm23-H1, but not of nm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancerY Tokunaga, T Urano, K Furukawa, et al.
Thrombosis Research|September 1, 1993
Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitusY Takada, T Urano, I Watanabe, et al.
Cancer|March 1, 1994
Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor disseminationM Nagayama, A Sato, H Hayakawa, et al.
The American Journal of Gastroenterology|December 1, 1991
Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinomaK Motojima, T Urano, Y Nagata, et al.
Thrombosis Research|July 1, 1991
Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasisK Sumiyoshi, S Baba, S Sakaguchi, et al.
Pageof 35

Showing results (151-160 of 345) with videos related to

Sort By:
Pageof 35
International Journal of Oncology|May 17, 2011
Frequent p53 mutations on exons-5 and exon-8 in human primary gastric-cancerS Fushida, T Urano, H Tsuruta, et al.
Thrombosis Research|October 1, 1990
Fluctuation of TPA and PAI-1 antigen levels in plasma: difference of their fluctuation patterns between male and femaleT Urano, K Sumiyoshi, M Nakamura, et al.
Thrombosis Research|October 15, 1990
Fluctuation of tPA and PAI-1 antigen levels in plasma: difference of their fluctuation patterns between male and femaleT Urano, K Sumiyoshi, M Nakamura, et al.
Neuroscience Research|April 22, 1999
Neuronal degeneration and a decrease in laminin-like immunoreactivity is associated with elevated tissue-type plasminogen activator in the rat hippocampus after kainic acid injectionN Nagai, T Urano, A Endo, et al.
American Heart Journal|May 29, 1999
Differential effects of enalapril and nitrendipine on the fibrinolytic system in essential hypertensionK Sakata, M Shirotani, H Yoshida, et al.
International Journal of Cancer|August 19, 1993
Reduced expression of nm23-H1, but not of nm23-H2, is concordant with the frequency of lymph-node metastasis of human breast cancerY Tokunaga, T Urano, K Furukawa, et al.
Thrombosis Research|September 1, 1993
Changes in fibrinolytic parameters in male patients with type 2 (non-insulin-dependent) diabetes mellitusY Takada, T Urano, I Watanabe, et al.
Cancer|March 1, 1994
Plasminogen activators and their inhibitors in non-small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor disseminationM Nagayama, A Sato, H Hayakawa, et al.
The American Journal of Gastroenterology|December 1, 1991
Mutations in the Kirsten-ras oncogene are common but lack correlation with prognosis and tumor stage in human pancreatic carcinomaK Motojima, T Urano, Y Nagata, et al.
Thrombosis Research|July 1, 1991
Increase in levels of plasminogen activator and type-1 plasminogen activator inhibitor in human breast cancer: possible roles in tumor progression and metastasisK Sumiyoshi, S Baba, S Sakaguchi, et al.
Pageof 35